gip/glp-1 receptor agonist drugs Dual agonists: New advances for treating type-2 diabetes Tirzepatide (LY3298176) is a Dual
Description
Feel lighter and more in control of your life
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality
The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally
Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
Regulatory submission for retatrutide is expected in 2026
